CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis ...Middle East

CHMP positive opinion is based on results from the Phase 3 SELECT-AXIS 2 study showing upadacitinib (RINVOQ®) met the primary endpoint of ASAS40 response at week 14 versus placebo1 Non-radiographic axial spondyloarthritis (nr-axSpA) is part of the axial spondyloarthritis (axSpA) spectrum...

Hence then, the article about chmp recommends approval of upadacitinib rinvoq for the treatment of adults with active non radiographic axial spondyloarthritis was published today ( Monday 27/06/2022 - 09:20 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis )

Also on site :

• A Recent Tragedy Has Left My Kids Devastated. But I’m Secretly Pleased.
• Watch last video of ‘All That’ star Kianna Underwood who died in hit-and-run at 33
• Refugee-student housing project in EU state rocked by rape scandal